On September 14 2019, Excelmab Inc. announced that USPTO authorised their core patent called "Multispecific antibody platform and related methods".
This patent protects the rights and interests of ExMab®, the core technology platform of Excelmab, including a new multifunctional antibody platform, multifunctional antibody and the method for producing such antibody. The patent obtained PCT approval in 2017 and was previously licensed in Australia.
The platform uses protein engineering to combine two different specific antibody molecules together to form stable, immunogenic molecule.
The technological innovation lies in introducing different amino acid mutations, such as two amino acids with opposite charges, into two different antibody heavy chains, so that the binding interfaces of the two chains have spatial complementarity and electrostatic attraction.
Excelmab is currently developing a variety of bispecific antibody drugs based on the ExMab® platform. The two most advanced drugs, EX101 (for breast and stomach cancer) and EX103 (for non-hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis), are expected to enter clinical trials in 2020.